ADVENTRX Presents Results at 4th Annual International AIDS Society
Conference
SAN DIEGO, July 23 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals
Inc. (Amex: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, announced today that it presented
results demonstrating synergistic HIV inhibitory activity of the Company's
broad spectrum antiviral drug candidate, ANX-201, when combined with
approved nucleoside and nucleotide reverse transcriptase inhibitors
(N(t)RTI) in preclinical tests. The results were presented at the 4th
Annual International AIDS Society (IAS) Conference on HIV Pathogenesis,
Treatment and Prevention in Sydney, Australia on July 23, 2007. The poster
entitled "Synergistic Antiretroviral Activity of Pyrophosphate Analogue
ANX-201 Paired with Nucleoside Reverse Transcriptase Inhibitors In Vitro"
was presented by Shani Waninger, Ph.D., associate director for research and
development for ADVENTRX.
"These preclinical results suggest that ANX-201 and commonly prescribed
N(t)RTIs represent a promising combination in multidrug antiretroviral
therapy," said Evan M. Levine, ADVENTRX's chief executive officer.
"Although ANX-201 and N(t)RTIs target the same viral enzyme, ANX-201 exerts
antiviral activity by a unique mechanism and represents a novel class of
reverse transcriptase inhibitor. These data suggest that ANX-201 in
combination with N(t)RTIs has potential clinical advantages for HIV
patients, including enhanced viral suppression and slowed progression of
drug resistance. We are excited about these results and expect to initiate
a clinical trial with ANX-201 as a component of multi-drug therapy for the
treatment of HIV later this year."
ANX-201 combined at fixed ratios with N(t)RTIs including zidovudine,
tenofovir, abacavir, lamivudine, emtricitabine and stavudine resulted in
synergistic to additive inhibition of HIV-1 in cultured human cells using
standard in vitro assays. Furthermore, this synergistic activity suggests
that the addition of ANX-201 to a drug regimen containing N(t)RTIs may have
clinical advantages that include enhanced antiviral activity and the
potential for reduced toxicity. A copy of the poster presentation is
available for download from the "Resources" section of the Company's web
site at http://www.adventrx.com under "Publications".
About ANX-201
ANX-201 (thiophosphonoformic acid) is a pyrophosphate analog and member
of a new class of reverse transcriptase inhibitor (RTI) for treatment of
resistant HIV patients. ANX-201 has shown activity against HIV
drug-resistant clinical isolates in preclinical studies. The resistance
profile of ANX-201 is unique among approved RTIs and has been shown to
resensitize NRTI-resistant virus. In preclinical studies, ANX-201 has shown
broad-spectrum antiviral activity against HIV-1, HIV-2, human and avian
influenza viruses, and herpes simplex viruses 1 and 2 (HSV-1 and HSV-2).
ADVENTRX plans to initiate a Phase 1/2 clinical trial of ANX-201 as a
component of multi-drug therapy for the treatment of HIV during 2007.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can be found
on the Company's web site at http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they materialize or
do not prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include, but are
not limited to: the validity of research results; the risk that preclinical
results are not indicative of the success of subsequent clinical trials and
that products will not perform as preclinical data suggests or as otherwise
anticipated; unexpected adverse side effects or inadequate therapeutic
efficacy of ANX-201 and other uncertainties inherent in the drug
development process; the timing and success of clinical trials;
difficulties or delays in developing, testing, manufacturing, and obtaining
regulatory approval for ANX-201, including receiving necessary regulatory
approvals for a Phase 1/2 clinical trial of ANX-201; the risk that ADVENTRX
will be unable to raise sufficient capital to fund the projects necessary
to meet its anticipated or stated goals and milestones, including funding
the continued development of ANX-201 for the treatment of HIV or human or
avian influenza; and other risks and uncertainties more fully described in
ADVENTRX's press releases and public filings with the Securities and
Exchange Commission. ADVENTRX's public filings with the Securities and
Exchange Commission are available at http://www.sec.gov. ADVENTRX does not
intend to update any forward-looking statement, including as set forth in
this press release, to reflect events or circumstances arising after the
date on which it was made.
SOURCE ADVENTRX Pharmaceuticals Inc.
 back to top
Related links:
http://www.adventrx.com
CONTACT:
Ioana C. Hone of ADVENTRX Pharmaceuticals,
+1-858-552-0866
|
